Role of antithrombotic agents in heart failure

Current Cardiology Reports

Volumn 14, Issue 3, 2012, Pages 314-325

  Cleland, John G F ^a   Mumtaz, Saqib ^a   Cecchini, Luca ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antithrombotic agents; Apixaban; Aspirin; Atrial fibrillation; Clopidogrel; Dabigatran; Heart failure; Randomized controlled trial; Rivaroxaban; Stroke; Sudden death; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RIVAROXABAN; TICAGRELOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; MEDICAL RESEARCH; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PROGNOSIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINUS RHYTHM; STROKE; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84861026766     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0266-x     Document Type: Review

References (106)

1. Cleland J G F. Is aspirin 'The Weakest Link' in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 2002;44:275-92.
2. Khand A, Rankin AC, Kaye GC, Cleland J G F. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614-32.
3. Khand A, Cleland J G F, Deedwania P. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev. 2002;7:267-83.
4. Cleland JG Time for a proper study of aspirin after a vascular event? BMJ. 2008;337:a2583.
5. Lip G Y H, Gibbs CR Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J An Coll Cardiol. 1999;33:1424-6.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke. 1991;22:983-9.
7. Good JM, Nihoyannopoulos P, Ghatei MA, et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J. 1994;15(12):1634-40.
8. Jhund PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. JACC. 2001;37:1234-8.
9. Davie AP, Love MP, McMurray J J V. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 2000;67(5):530-7.
10. Habib F, Dutka D, Crossman D, Oakley CM, Cleland J G F. Enhanced basal nitric oxide production in heart failure: another failed counter regulatory vasodilator mechanism? Lancet. 1994;344(8919):371-3.
11. Haynes G, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci. 1993;84:427-33.
12. de Silva R, Nikitin NP, Witte KK, et al. Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. Eur J Heart Fail. 2007;9:415-23.
13. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 1993;87(6):1873-9.
14. Knottenbelt C, Brennan PJ, Meade TW. For the MRC general practice research framework. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med. 2002;162:881-6.
15. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295-302.
16. van Dantzig JM, Becker AE. Sudden cardiac death and acute pathology of coronary arteries. Eur Heart J. 1986;7(11):987-91.
17. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103(7):934-40.
18. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland J G F. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J. 1994;127:607-12.
19. Loh PH, Tin L, Goode K, Windram J, Reddy P. Disturbed haemostasis predicts mortality in patients with heart failure due to left ventricular systolic dysfunction. Eur Heart J. 2007;28(Abstr Suppl):810.
20. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001;103:1746-51.
21. Kannel WB, Abbott RD. Incidence and prognosis of unrecognised myocardial infarction: an update on the Framingham Study. N Engl J Med. 1984;311:1144-7.
22. Perna ER, Macin SM, Parras JI, et al. Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary oedema. Am Heart J. 2002;143:814-20.
23. Uretsky B, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival study (ATLAS) trial. Circulation. 2000;102:611-6.
24. Dormandy JA, Charbonnel B, Eckland D J A, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
25. Hansson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.
26. Cleland J G F, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1:41-5.
27. Cleland J G F, Thygesen K, Uretsky BF, et al. Cardiovascular critical event pathways for the progression of heart failure. A report from the ATLAS study. Eur Heart J. 2001;22:1601-12.
28. Schmidt R, Fazekas F, Offenbacher H, Dusleag J, Lechner H. Brain magnetic resonance imaging and neuropsychological evaluation of patients with idiopathic dilated cardiomyopathy. Stroke. 1991;22:195-9.
29. Cleland J G F. anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 1997;12:276-87.
30. Cleland J G F, Thackray S. Antiplatelet therapy for ACS: a house in need of a spring clean. Prescriber. 2009;20(23/24):7-10.
31. Loh E, Sutton MS, Wun C-CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-7.
32. Levine M, Gent M, Hirsh J, et al. A comparison of lowmolecular-weight heparin administered primarily at home with unfranctionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81.
33. Darze ES, Latado AL, Guimaraes AG, et al. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest. 2005;128(4):2576-80.
34. Darze ES, Latado AL, Guimaraes AG, et al. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest. 2007;131(6):1838-43.
35. Orn S, Cleland JG, Romo M, Kjekshus J, Dickstein K. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med. 2005;118(7):752-8.
36. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-442.
37. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
38. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112:154-235.
39. Cleland J G F, Oakley CM. Vascular tone in heart failure: the neuroendocrine-therapeutic interface. Br Heart J. 1991;66:264-7.
40. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61.
41. MacIntyre IM, Jhund PS, McMurray JJ. Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovasc Drugs Ther. 2005;19(4):261-5.
42. Davie AP, Love MP, McMurray J J V. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharm Ther. 2000;67:530-7.
43. Meune C, Mahe I, Mourad JJ, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail. 2003;5(3):271-9.
44. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20:1549-55.
45. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419-25.
46. Weil J, Colin-Jones D, Langman M, et al. Prophylactic use of aspirin and risk of peptic ulcer bleeding. Br Med J. 1995;310:827-30.
47. Kelly MJ, Kaugman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348(9039):1413-6.
48. Weil J, Langman M J S, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal antiinflammatory drugs. Gut. 2000;46:27-31.
49. de Silva R, Rigby AS, Witte K K A, et al. Anemia, renal dysfunction and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98(3):391-8.
50. Teo K, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360(9339):1037-43.
51. Cleland JG, Torabi A, Zhang J, Chelliah RK. Anti-thrombotic Agents. In: McDonagh TA, Gardner RS, Clark AL, Dargie HJ (eds) Oxford textbook of heart failure. Oxford; 2011; pp. 437-46.
52. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368(9535):581-8.
53. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. For the MOCHA Investigators. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with betablockers. J Am Coll Cardiol. 2001;38(7):1950-6.
54. Cleland J G F, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14-21.
55. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011;32(23):2945-53.
56. Sanada S, Asanuma H, Koretsune Y, et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Hypertens Res. 2007;30(10):913-9.
57. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-51.
58. Meune C, Wahbi K, Fulla Y, et al. Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. Eur J Heart Fail. 2007;9(2):197-201.
59. Jug B, Sebestjen M, Sabovic M, Keber I. Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. J Card Fail. 2006;12(6):446-51.
60. Meune C, Mahe I, Cohen-Solal A. Comparative effect of aspirin and clopidogrel on arterial function in CHF. Int J Cardiol. 2006;106(1):61-6.
61. Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J. 1999;138:254-60.
62. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997;95:1930-6.
63. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol. 2003;91(11):1350-2.
64. Bhatt DL, Chew DP, Hirsch AT, Ringleb PB, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363-8.
65. Cleland J G F, Cohen-Solal A, Cosin-Aguilar J, et al. An International Survey of the Management of Heart Failure in Primary Care. The IMPROVEMENT of Heart Failure Programme. Lancet. 2002;360:1631-9.
66. Cleland J G F, Swedberg K, Follath F, et al. The EuroHeart Failure Survey Programme: survey on the quality of care among patients with heart failure in Europe. Part 1: Patient Characteristics and Diagnosis. Eur Heart J. 2003;24:422-63.
67. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. JACC. 1998;31:749-53.
68. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
69. Cleland J G F, Shelton R, Nikitin NP, Ford S, Frison L, Grind M. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail. 2007;9(6-7):730-9.
70. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
71. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.
72. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
73. The WASH study steering committee and investigators. The WASH study (Warfarin/Aspirin Study in Heart failure): rationale, design and endpoints. Eur J Heart Fail. 1999;1:95-9.
74. Cleland J G F, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-64.
75. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8(4):428-32.
76. Massie B, Collins JF, Ammon SE, et al. Randomized Trial of Warfarin, Aspirin and Clopidogrel in Patients with Chronic Heart Failure. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure WATCH) Trial. Circulation. 2009;119(12):1616-24.
77. Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS. Warfarin versus aspirin in patients with reduced cardiac ejection (WARCEF): rationale, objectives, and design. J Card Fail. 2006;12(1):39-46.
78. Shelton RJ, Clark AL, Kaye GC, Cleland J G F. The atrial fibrillation paradox of heart failure. Congest Heart Fail. 2010;16(1):3-9.
79. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: The V-HeFT studies. Circulation. 1993;87:VI102-10.
80. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26:1303-8.
81. Cleland J G F, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomised clinical trials. Eur Heart J. 1996;17:674-81.
82. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12.
83. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066- 78.
84. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7.
85. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341-6.
86. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77.
87. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev. 2009; (3): CD003747.
88. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enxoaparin with placebo for the prevention of venous thromboembolismin acutely ill medical patients. N Engl J Med. 1999;341:793-800.
89. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or clacium channel blocker versus diuretic (ALLHAT). JAMA. 2002;288:2981-97.
90. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.
91. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
92. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
93. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.
94. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
95. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-45.
96. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30.
97. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
98. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
99. Yusuf S, Nicklas JM, Timmis G, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
100. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
101. Poole-Wilson PA, Swedberg K, Cleland J G F, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
102. Remme W, Torp-Pedersen C, Cleland JG, et al. Carvedilol protects better against vascular events than Metoprolol in Heart Failure. Results from COMET. J Am Coll Cardiol. 2007;49(9):963-71.
103. Young JB, Dunlap ME, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction results of the CHARM Low-left ventricular ejection fraction trials. Circulation. 2004;110:2618-26.
104. Solomon SD, Wang D, Finn P, et al. Effect of Candesartan on cause-specific mortality in heart failure patients. The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation. 2004;110:2180-3.
105. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54(20):1850-9.
106. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 November 11